Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2012. The report serves as a notification of transactions involving a Person Discharging Managerial Responsibility (PDMR) in the company's Ordinary shares, rather than a comprehensive financial results report.
Key Financial Metrics
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific executive compensation event.
Material Changes
The material change reported is a transaction involving Dr. P J T Vallance. Following the vesting on January 29, 2012, of 25% of an award made on January 29, 2007, under the GlaxoSmithKline Deferred Investment Award Plan, Dr. Vallance is scheduled to receive a cash payment. The payment details are as follows:
- Payment Amount: 1433.25p per share
- Share Count: 4703.976 notional Ordinary shares
- Payment Date: February 20, 2012
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a regulatory disclosure required under Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Verify the vesting schedule and terms of the GlaxoSmithKline Deferred Investment Award Plan for awards made in 2007.
- Confirm the calculation of the cash payment (1433.25p per share) against the market price or plan valuation on the vesting date.
- Check subsequent filings to confirm the actual payment was made on February 20, 2012.